Needham analyst Gil Blum downgraded Rocket Pharmaceuticals (RCKT) to Hold from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Resilience and Proactive Measures: Rocket Pharmaceuticals’ Path to Overcoming Clinical Challenges and Future Success
- Rocket’s Danon update raises specter of worst-case scenario, Leerink says
- Rocket Pharmaceuticals price target lowered to $16 from $32 at Wedbush
- Rocket Pharmaceuticals Stock (RCKT) Plummets 57% on FDA Intervention
- Morning Movers: Informatica and Salesforce gain after $8B transaction